Galmed Pharmaceuticals Ltd (GLMD) Stock AnalysisGLMDStock AnalysisGalmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Galmed Pharmaceuticals Ltd (GLMD) is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $4.17, and the stock has experienced a year-to-date change of -36.73%. Additionally, the RSI is at 39.53, indicating that the stock is nearing oversold territory but has not yet shown signs of recovery. The main risk is the negative net income, which was -4,818,000 USD in Q4 2025, reflecting ongoing financial struggles.

5 analysts cover GLMD: 5 rate it Buy, 0 Hold and 0 Sell.